Novartis Ag (NVS) Accumulated Expenses (2017 - 2025)

Novartis Ag's Accumulated Expenses history runs 9 years deep, the most recent figure standing at $1.0 billion for Q4 2025.

• In Q4 2025, Accumulated Expenses rose 518.34% year-over-year to $1.0 billion; the TTM figure through Dec 2025 stood at $1.0 billion (up 518.34% YoY), while the FY2025 annual figure was $1.0 billion, up 518.34% from the prior year.
• Accumulated Expenses came in at $1.0 billion for Q4 2025 at Novartis Ag, up from $169.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.1 billion in Q4 2022 to a low of $116.0 million in Q4 2023.
• A 5-year average of $421.9 million and a median of $182.0 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 733.86% in 2022 and tumbled 89.05% in 2023, its largest moves.
• Novartis Ag's Accumulated Expenses stood at $127.0 million in 2021, then surged by 733.86% to $1.1 billion in 2022, then sank by 89.05% to $116.0 million in 2023, then jumped by 45.69% to $169.0 million in 2024, then soared by 518.34% to $1.0 billion in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.0 billion, $169.0 million, and $116.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison